大腸炎(Colitis):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Colitis - Pipeline Review, H1 2015
◆商品コード:GMDHC6153IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:74
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における大腸炎(Colitis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・大腸炎(Colitis)の概要
・大腸炎(Colitis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・大腸炎(Colitis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・大腸炎(Colitis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・大腸炎(Colitis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Colitis – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Colitis – Pipeline Review, H1 2015’, provides an overview of the Colitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Colitis Overview 8
Therapeutics Development 9
Pipeline Products for Colitis – Overview 9
Pipeline Products for Colitis – Comparative Analysis 10
Colitis – Therapeutics under Development by Companies 11
Colitis – Therapeutics under Investigation by Universities/Institutes 13
Colitis – Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Colitis – Products under Development by Companies 16
Colitis – Products under Investigation by Universities/Institutes 17
Colitis – Companies Involved in Therapeutics Development 18
Ajinomoto Pharmaceuticals Co., Ltd. 18
Akebia Therapeutics, Inc. 19
BioLineRx, Ltd. 20
Cognosci, Inc. 21
Galapagos NV 22
GeneFrontier Corporation 23
Inovio Pharmaceuticals, Inc. 24
N30 Pharmaceuticals 25
Prokarium Ltd. 26
Protalix BioTherapeutics, Inc. 27
Synovo GmbH 28
Colitis – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AcTMP-1 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AKB-6899 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
APY-0201 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BC-1215 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BL-5040 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
C-142 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
clostridium difficile vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
COG-112 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CSY-0073 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
etanercept biosimilar – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgotinib – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GFC-101 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
N-6022 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
N-6547 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NK-007 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptide to Inhibit NFkB for Colitis and Enteritis – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RNAi Oligonucleotides to Inhibit TNFalpha for IBD and Colitis – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecule for Colitis – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Synthetic Peptides to Inhibit Panx1 for Colitis – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Vaccine for Colitis – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Vaccine to Target Interleukin-23 for Colitis – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VGX-1027 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Colitis – Recent Pipeline Updates 63
Colitis – Dormant Projects 70
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

[List of Tables]
Number of Products under Development for Colitis, H1 2015 9
Number of Products under Development for Colitis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 18
Colitis - Pipeline by Akebia Therapeutics, Inc., H1 2015 19
Colitis - Pipeline by BioLineRx, Ltd., H1 2015 20
Colitis - Pipeline by Cognosci, Inc., H1 2015 21
Colitis - Pipeline by Galapagos NV, H1 2015 22
Colitis - Pipeline by GeneFrontier Corporation, H1 2015 23
Colitis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 24
Colitis - Pipeline by N30 Pharmaceuticals, H1 2015 25
Colitis - Pipeline by Prokarium Ltd., H1 2015 26
Colitis - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 27
Colitis - Pipeline by Synovo GmbH, H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Colitis Therapeutics - Recent Pipeline Updates, H1 2015 63
Colitis - Dormant Projects, H1 2015 70
Colitis - Dormant Projects (Contd..1), H1 2015 71
Colitis - Dormant Projects (Contd..2), H1 2015 72

[List of Figures]
Number of Products under Development for Colitis, H1 2015 9
Number of Products under Development for Colitis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 29
Number of Products by Top 10 Targets, H1 2015 30
Number of Products by Stage and Top 10 Targets, H1 2015 31
Number of Products by Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Top 10 Routes of Administration, H1 2015 34
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35
Number of Products by Top 10 Molecule Types, H1 2015 36
Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

【掲載企業】

Ajinomoto Pharmaceuticals Co., Ltd.
Akebia Therapeutics, Inc.
BioLineRx, Ltd.
Cognosci, Inc.
Galapagos NV
GeneFrontier Corporation
Inovio Pharmaceuticals, Inc.
N30 Pharmaceuticals
Prokarium Ltd.
Protalix BioTherapeutics, Inc.
Synovo GmbH

★調査レポート[大腸炎(Colitis):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6153IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[大腸炎(Colitis):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆